---
layout: post
title: "健康元：吸入制剂在研产品逐步进入中后期"
date: 2022-05-23 17:08:25 +0800
categories: jiemianxinwen
tags: 界面新闻新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600380" data-code="600380|1|1" data-code2="600380|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600380&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600380_0" data-code="K 600380|1|1" data-code2="K 600380|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>健康元5月23日公布投资者关系活动记录表，表示吸入制剂在研产品逐步进入中后期，公司陆续进入收获期。妥布霉素吸入溶液、富马酸福莫特罗吸入溶液、丙酸氟替卡松吸入混悬液、硫酸特布他林雾化液均已报产，沙美特罗氟替卡松吸入粉雾剂、马来酸茚达特罗吸入粉雾剂等开展临床试验。<br /></p><p class="em_media">（文章来源：界面新闻）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202205232388376270>

[返回界面新闻新闻](//finews.withounder.com/category/jiemianxinwen.html)｜[返回首页](//finews.withounder.com/)